Roy Fleischmann
Impact in
- Rheumatology top 0.01%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Hematology top 0.1%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 263
- Rheumatoid Arthritis Research and Therapies 231
- Systemic Lupus Erythematosus Research 32
- Spondyloarthritis Studies and Treatments 29
- Hematology 47
- Autoimmune and Inflammatory Disorders Research 46
- Co-authors
- Michael H. Schiff (26 shared papers)Joel M. Kremer (15 shared papers)Mark C. Genovese (30 shared papers)Ronald van Vollenhoven (24 shared papers)Larry W. Moreland (8 shared papers)Edward Clark Keystone (19 shared papers)Michael E. Weinblatt (20 shared papers)Désirée van der Heijde (27 shared papers)
- Journals
- Annals of the Rheumatic Diseases (61 papers)Lara D. Veeken (31 papers)RMD Open (26 papers)Rheumatology and Therapy (18 papers)Arthritis Research & Therapy (13 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Roy Fleischmann
323 papers receiving 26.8k citations
Roy Fleischmann's Hit Papers
Peers
Comparison fields: 5 of 147
- Rheumatology 18.0k
- Hematology 5.1k
- Immunology 5.3k
- Genetics 2.3k
- Pathology and Forensic Medicine 1.8k
Countries citing papers authored by Roy Fleischmann
This map shows the geographic impact of Roy Fleischmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Fleischmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Fleischmann more than expected).
Fields of papers citing papers by Roy Fleischmann
This network shows the impact of papers produced by Roy Fleischmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Fleischmann. The network helps show where Roy Fleischmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Roy Fleischmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 329 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate Hit paper breakdown → | 1999 | 1759 |
| 2 | A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis Hit paper breakdown → | 2000 | 1491 |
| 3 | Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein Hit paper breakdown → | 1997 | 1377 |
| 4 | Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis Hit paper breakdown → | 2022 | 1246 |
| 5 | Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Hit paper breakdown → | 2012 | 862 |
| 6 | The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial Hit paper breakdown → | 2006 | 860 |
| 7 | Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Hit paper breakdown → | 2012 | 806 |
| 8 | Tofacitinib versus Methotrexate in Rheumatoid Arthritis Hit paper breakdown → | 2014 | 651 |
| 9 | Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial Hit paper breakdown → | 2003 | 632 |
| 10 | Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes Hit paper breakdown → | 2002 | 612 |
| 11 | Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2020 | 495 |
| 12 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Hit paper breakdown → | 2013 | 483 |
| 13 | Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | 2003 | 430 |
| 14 | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Hit paper breakdown → | 2017 | 412 |
| 15 | Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis Hit paper breakdown → | 2013 | 395 |
| 16 | Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Hit paper breakdown → | 2013 | 390 |
| 17 | Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial Hit paper breakdown → | 2018 | 370 |
| 18 | 2010 | 367 | |
| 19 | 2009 | 357 | |
| 20 | Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial Hit paper breakdown → | 2019 | 351 |
About Roy Fleischmann
Roy Fleischmann is a scholar working on Rheumatology, Hematology, Genetics, Immunology and Pathology and Forensic Medicine, having authored 329 papers that have together received 28.2k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (231 papers), Autoimmune and Inflammatory Disorders Research (46 papers), Systemic Lupus Erythematosus Research (32 papers), Spondyloarthritis Studies and Treatments (29 papers), Chronic Lymphocytic Leukemia Research (26 papers), Biosimilars and Bioanalytical Methods (14 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Lymphoma Diagnosis and Treatment (11 papers). The work is most often cited by research in Rheumatology (18.0k citations), Hematology (5.1k citations), Immunology (5.3k citations), Genetics (2.3k citations) and Pathology and Forensic Medicine (1.8k citations). Roy Fleischmann has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Michael H. Schiff, Joel M. Kremer, Mark C. Genovese, Ronald van Vollenhoven, Larry W. Moreland, Edward Clark Keystone, Michael E. Weinblatt, Désirée van der Heijde, David C. Gruben and Gene V. Wallenstein. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, RMD Open, Rheumatology and Therapy and Arthritis Research & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.